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Metastasis is the primary cause of death in cancer patients and current treatments fail to
provide durable responses. Efforts to treat metastatic disease are hindered by the fact that
metastatic cells often remain dormant for prolonged intervals of years, or even decades.
Tumor dormancy reflects the capability of disseminated tumor cells (DTCs), or micrometa-
stases, to evade treatment and remain at low numbers after primary tumor resection. Un-
fortunately, dormant cells will eventually produce overt metastasis. Innovations are
needed to understand metastatic dormancy and improve cancer detection and treatment.
Currently, few models exist that faithfully recapitulate metastatic dormancy and metas-
tasis to clinically relevant tissues, such as the bone. Herein, we discuss recent advances
describing genetic cell-autonomous and systemic or local changes in the microenviron-
ment that have been shown to endow DTCs with properties to survive and eventually colo-
nize distant organs.
ª 2016 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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123Despite advances in clinical oncology and basic cancer
research, metastasis continues to be a lethal hallmark of can-
cer. In this process, malignant cells spread from the primary
tumor to distant sites, where they resist conventional treat-
ments, proliferate, and cause failure of a vital organ. Systemic
dissection of the molecular, cellular, genetic, and clinical
mechanisms underlying metastatic progression may lead to
the development of new diagnostic and therapeutic strategies
to prevent and treat metastases. However, there are some fac-
tors that challenge metastasis research, which include theInstitute for Research in B
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R.R., Gawrzak, S., Tumoof primary tumors, genetic heterogeneity of cancer cells in the
primary and secondary sites, and complex interactions be-
tween cancer cells and the microenvironment. In line with
this, cancer types show distinct metastatic organ tropism. In
addition, although steps in the metastatic cascade are part
of a continuous biological sequence, their acquisition may
vary from one tumor type to another. The classical simplifica-
tion of metastasis into an orderly sequence of basic step-
sdlocal invasion, intravasation, survival in circulation,
extravasation, and colonizationdhas helped to rationalize
the complex set of biological properties required for aiomedicine (IRB Barcelona), PBB52 Parc Cientıfic de Barcelona, C/
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MOLONC844_proof ■ 12 October 2016 ■ 2/13particular malignancy to progress towards overt metastatic
disease (Gupta and Massague, 2006). Moreover, a progress in
understanding the kinetics of the metastasis has been made
in the past decade. This review focuses on the current knowl-
edge of cancer dormancy, in particular the molecular mecha-
nisms governing this state. The slow progression of certain
subtypes of cancer under the distinct selective conditions pre-
sent in various tissues gives rise to metastatic speciation. This
speciation is reflected by the distinct kinetics of cancer relapse
to different sites in the same patient and by the coexistence of
malignant cells that differ in organ tropism in patient-derived
samples (Bos et al., 2009; Gupta et al., 2007; Padua et al., 2008;
Zhang et al., 2009; Lu et al., 2011; Lu et al., 2009).
After removal of the primary tumor, metastasis may occur
after a longperiodmarkedby the absenceof clinical symptoms.
Tumordormancy reveals the capacity of circulating tumor cells
(CTCs), disseminated tumor cells (DTCs) and/ormicrometasta-
ses to remain at low numbers after primary tumor resection.
These cells go undetected for long periodsdsometimes years
or even decadesdand may explain prolonged asymptomatic
residual disease and treatment resistance. Unfortunately,
dormant cells will eventually produce overt metastasis, thus
causing a fatal condition. As we start to unveil more about the
biologyof cancer cells,wecanbegin toaddresshowbest to treat
asymptomatic residual disease. Bone metastasis-targeted
treatments represent a major advance in our understanding
of tissue-specific metastatic mechanisms and their potential
use in prevention opens up new clinical avenues. However,
key to determiningwhether dormant solitary cells ormicrome-
tastases represent valid targets is knowledge of the underlying
biology of dormancy and the probability of cells progressing to
active metastatic growth. This progression is poorly under-
stood in preclinical models and even less so in the clinical
context. Only through the combination and integration of can-
cer genetics, cell biology, cell signaling, mouse models of can-
cer, and cellular metastatic functions we will be able to
address the following questions: What are the unique require-
ments of dormant metastatic cancer cells? How can we use
this knowledge to improve current therapies?When these ther-
apies shall be delivered to effectively tackle the disease? All
these questions are discussed herein.111
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1302. Dormancy in the temporal course of metastasis
Although the steps of the metastatic cascade are, to certain
extent, uniform for most types of carcinoma, the kinetics of
metastasis are highly dependent on the tumor type. Clinically
detectable distant metastasis can occur simultaneously with
primary tumor diagnosis or within a time ranging fromweeks
to decades (Figure 1). The period between primary tumor
detection and metastatic relapse is often defined as latency.
The duration of metastatic latency varies between cancer
types, and for the most aggressive ones it is very short, result-
ing in high relapse and mortality rates following diagnosis. In
lung cancer, the metastatic latency interval usually lasts only
a few weeks, thus 5-year survival rates are estimated to be
around 17% (Howlader et al., 2016). The relapse rate is lower,
reaching 30e40% in stage I lung adenocarcinoma patients
(Nesbitt et al., 1995). In this type of cancer, malignant cellsPlease cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009acquiremetastatic traits for rapid andmassive cell dissemina-
tion, followed by colonization of multiple secondary organs.
Sequential metastasis to liver and lungs is often observed in
colorectal cancer progression, and more than 85% of recur-
rences are detected within the first 3 years of follow-up in
advanced tumors (Nguyen et al., 2009). Therefore, this partic-
ular type of cancer shows medium latency and aggressive-
ness, resulting in a 5-year survival rate of 65% (Howlader
et al., 2016). A well-known example of a tumor type with
very long latency is prostate cancer. According to statistics
from the National Cancer Institute, nearly 100% of diagnosed
patients survive 5 years, and 82% are still alive 15 years after
diagnosis (the most recent statistics report a 15-year survival
rate of 94% for patients diagnosed after 1994, regardless of
the stage) (Howlader et al., 2016). The short latency in lung
cancer implies that malignant cells in the primary tumor ac-
quire most of the metastatic traits, thus enabling them to
overtake organs immediately after infiltration. However, in
long latent metastasis, early seeded CTCs and DTCs need
time to alter or unleash the functions required for tumor initi-
ation and expansion in the secondary site. In this case, the
microenvironment of the host organ plays a key role in the
acquisition of these functions (Obenauf and Massague, 2015).
In contrast to the other types of carcinoma discussed above,
breastcancercanbeclassifiedasbothamediumand long latent
disease (Figure 1).Metastasis inbreast cancer usuallymanifests
asynchronously with the primary tumor and shows variable
time to become clinically detected. This lag depends on the vol-
ume, stage, and molecular subtype of the primary tumor. In
addition to these factors, estrogen receptor (ER) status is also
related to time to recurrence (Figure 2). ER tumors are charac-
terized by a more aggressive spread, thus recurrence peaks at
around2yearsafterdiagnosis.However, therelapseratedimin-
ishes to a low level 5 years after diagnosis. Therefore ER sub-
types are classified as either short or medium latent cancer
types (Hess et al., 2003; Early Breast Cancer Trialists’
Collaborative, 2005; Zhang et al., 2013). In contrast, theERþ sub-
type has a lower risk of recurrence than the former in the initial
5 years after diagnosis, but has a greater chronic annual risk of
recurrence thereafter. Thus, more than half of the metastases
of ERþ tumors occur 5 years or longer after diagnosis and surgi-
cal removal of theprimary tumor.Moreover, somepatients suf-
fer recurrence after more than 20 years (Hess et al., 2003; Early
Breast Cancer Trialists’ Collaborative, 2005). In addition, ERþ
subtypes show higher rates of heterogeneity during the course
ofmetastasis. In this regard, some patientswill developmetas-
tasis shortly after diagnosis and others after long latency. Strik-
ingly, 15-year recurrence and mortality rates for ER and ERþ
subtypes are similar in patients diagnosed at early stages of
thedisease (GossandChambers, 2010). Late recurrencedecades
after the initial diagnosis indicates a long latency in ERþ breast
cancer metastatic progression. However, metastasis in some
ERþ patients progresses rapidly, implying broad heterogeneity
in recurrence patterns.3. The metastatic cascade and dormancy
The metastatic cascade is a series of stochastic events that
collectively lead to the formation of overt metastases in ar cell dormancy, Molecular Oncology (2016), http://dx.doi.org/
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Figure 1 e The temporal course of cancer metastasis. Metastatic relapse may occur within months, years or decades after primary tumor diagnosis,
removal, and systemic treatment. Different cancer types exhibit variability in length of the latency: short for lung cancer (red), middle for colon
cancer and ERL breast cancer (yellow), and long for prostate cancer and ERD breast cancer (blue). Dashed line indicates threshold of detection
symptomatic metastases.
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MOLONC844_proof ■ 12 October 2016 ■ 3/13distant organ. It involves the following seven steps: invasion,
intravasation, dissemination in the circulation and survival,
arrest at a distant site, extravasation, tumor initiation, and,
finally, outgrowth and clinical manifestation (Obenauf and
Massague, 2015; Valastyan and Weinberg, 2011) (Figure 3).
Metastasis is a highly inefficient process in which each step
of the cascade is a bottleneck for cancer cells and drives clonal
selection. By the end of this process, only a small fraction of
thousands of cells seeded daily reinitiate a tumor in a distant
site. Studies based on experimental models estimate that
0.02% of melanoma cells succeed in colonizing liver after in-
jection into a portal vain and similar results were obtained
in lung colonization assay (Luzzi et al., 1998; Cameron et al.,50 10 15 20
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Figure 2 e The temporal course of breast cancer metastasis. ERL
breast cancer subtypes metastases typically occur within 5 years after
primary tumor diagnosis (grey) whereas ERD can relapse early (before
5 years) or late, up to decades after initial diagnosis (orange). Dashed
line indicates clinical threshold for early and late relapse.
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10.1016/j.molonc.2016.09.0092000). In order to metastasize, cancer cells must orchestrate
diverse cellular functions to overcome the difficulties of the
metastatic cascade. These functions are not only limited to
cell-autonomous traits, but also highly depend on the interac-
tion of the metastatic cell with the tumor and host stroma. In
some cases, several functions are required to implement a
single step, whereas others may influence multiple ones.
From a mechanistic perspective, genetic, epigenetic and
translational traits alter the expression of promoter and sup-
pressor genes, which, when combined with extended periods
of dormancy, may determine metastatic latency and eventu-
ally facilitate overt clinical metastasis.
Metastasis originates in the primary tumor invasive front,
where cancer cells migrate toward surrounding tissues. To
achieve thismovement, cellmotility is altered by cytoskeleton
reorganization and the secretion of extracellular matrix (ECM)
remodelers, mainly proteases (Kessenbrock et al., 2010; Wolf
et al., 2007). Tumor stroma composed of tumor-associated
macrophages and fibroblasts supports the invasion of meta-
static cells by secreting pro-migratory factors (Qian and
Pollard, 2010; Joyce et al., 2004; Dumont et al., 2013). In order
to intravasate, metastatic cells undergo an epithelial-to-
mesenchymal transition (EMT). The loss of epithelial features,
like adhesion or polarization, followed by gain of invasive-
ness, greatly contributes to metastasis. In this regard, the
downregulation of epithelial protein E-cadherin is a well-
established prognostic marker of metastasis (Vleminckx
et al., 1991; Berx and van Roy, 2009). Successful intravasation
also requires the formation of a new vasculature in the pri-
mary tumor by angiogenesis promoters. This neovasculaturer cell dormancy, Molecular Oncology (2016), http://dx.doi.org/
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Figure 3 e The metastatic cascade. Metastasis progresses through the sequence of steps that promote malignant cells, from primary tumor, to
disseminate and colonize distant organ. Acquisition of each step is driven by specific cellular functions. Cascade steps are indicated in grey blocks,
cell autonomous functions in important in each step in black, circulating tumor cell in green, and disseminated tumor cell in blue.
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MOLONC844_proof ■ 12 October 2016 ■ 4/13is often leaky and covered by abnormal pericytes which
makes it accessible for metastatic cells (Morikawa et al.,
2002). In addition, metastatic cells secrete factors that further
increase vessel permeability, thereby facilitating their entry
into the circulation. Various mediators are involved in this
process, including transforming growth-factor beta (TGFb),
and molecules produced by supportive tumor stroma, namely
epidermal growth factor (EGF) and colony-stimulating factor 1
(CSF-1) (Wyckoff et al., 2007; Giampieri et al., 2009). The blood-
stream or lymphatic system is a hostile environment for can-
cer cells, and transition through vessels results inmassive cell
death. On the one hand, cells are challenged by innate im-
mune natural killer (NK) cells and, on the other, they die
from mechanical damage (Massague and Obenauf, 2016;
Nieswandt et al., 1999). In order to enhance survival in the cir-
culation, cancer cells associate with blood platelets or adhere
to the endothelium at the destination site (Labelle et al., 2011;
Valiente et al., 2014). After reaching the secondary site, meta-
static cells are arrested in themicrovasculature of the host or-
gan prior to extravasation. Adhesion and interaction between
CTCs and the host stroma facilitatemicrovasculature trapping
(Labelle and Hynes, 2012). Extravasation in bone or liver is
facilitated by extrinsic factors such as the permeability of cap-
illaries. In other organs, such as the lungs, cancer cells acquire
new functions in order to cross the vessel walldcomposed of
endothelial cells, basement membrane and tissue-specific
cellsdand enter the parenchyma (Padua et al., 2008; Lawler,
2002). Vessel remodeling can be achieved by cancer cell-
secreted factors that increase the permeability of the endothe-
lium. In the case of lung metastasis, angiopoietin-like 4
(ANGLPTL4) disrupts cell junctions in the vascular endothe-
lium (Padua et al., 2008), and parathyroid hormone-like hor-
mone (PTHLH) induces endothelial cell death (Urosevic et al.,
2014).
Once metastatic cells extravasate and settle in the second-
ary site as DTCs, they must adapt to the microenvironment of
the host organ in order to achieve homing to a distant loca-
tion. Organ-specific extrinsic factors, including stroma cells,
ECM, cytokines, and growth factors, compromise the survival
of DTCs. To overcome these obstacles, metastatic cells use
cell-autonomous traits that facilitate homing and survival byPlease cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009altering SRC tyrosine kinase signaling (Zhang et al., 2009) or
the p38 and ERK MAPKinase signaling pathways (Adam
et al., 2009). Similarly, they also favor stem-cell-like character-
istics by repressing metastasis suppressor genes (Morales
et al., 2014) and expressing the sex determining region Y-box
2 and 9 (SOX2 and SOX9) transcription factors (Malladi et al.,
2016; Torrano et al., 2016). These cells also improve homing
and micrometastasis formation by creating pre-metastatic
niches at the destination. In this scenario, the primary tumor
secretes systemic factors to prime tissues at the secondary
site. Consequently, cells extravasate to a more permissive
microenvironment. In this regard, the enzyme lysyl oxidase
is a potent pre-metastatic niche regulator (Erler et al., 2009).
Tenascin C is another example of an ECM protein secreted
by breast cancer metastatic cells to create a supportive niche
in lungs (Oskarsson et al., 2011). Moreover, exosomes have
recently been shown to promote pre-metastatic niche forma-
tion (Peinado et al., 2012). Recent studies have also shown that
various stroma cells, including fibroblasts, neutrophils and
vascular endothelial growth factor receptor 1 (VEGFR1)-posi-
tive bone marrow-derived hematopoietic progenitor cells,
play a central role in niche preparation (Malanchi et al.,
2012;Wculek andMalanchi, 2015; Kaplan et al., 2005). Another
trait improving survival ofmetastatic cells in a distant organ is
sometimes linked to a transitorymesenchymal state of cancer
cells when disseminated (Del Pozo Martin et al., 2015; Ocana
et al., 2012). This mesenchymal temporarily state reverts
upon reaching metastatic site, which explains why
carcinoma-derivedmetastases show epithelial characteristics
and resemble, to certain extent, the primary tumor (Brabletz,
2012). Importantly, this process includes escape from immune
responses, which are partly responsible for keeping dissemi-
nated cancer cells in check (Malladi et al., 2016). Whereas
some lesions expand rapidly, in many tumor types DTCs are
arrested and remain dormant for many years.
The last step in themetastatic cascade is the overgrowth of
micrometastases into full-blown symptomatic lesions that
are clinically detectable. Metastatic cells extensively prolifer-
ate, causing failure of vital organs. This metastatic virulence
is driven in an organ-specific manner and depends on a
wide range of intrinsic and extrinsic mechanisms (whichr cell dormancy, Molecular Oncology (2016), http://dx.doi.org/
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Massague, 2015)).
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1304. Minimal residual disease and dormancy
In metastatic latency, malignant cells that survived treatment
and are neither detectable by conventional tests nor manifest
symptoms contribute to minimal residual disease. Therefore,
CTCs and DTCs in patients’ blood or bone marrow are direct
evidence of minimal residual disease in metastatic latency
and risk factors for recurrence (Aguirre-Ghiso, 2007). Strik-
ingly, metastatic cells from minimal residual disease can be
transferred through organ transplants. Organs from donors
diagnosed with melanoma, but successfully treated and clin-
ically disease-free for over 10 years, develop metastases after
transplantation (Stephens et al., 2000; Strauss and Thomas,
2010). The isolation of CTCs from the blood of cancer patients
offers valuable information about disease progression and
treatment design. CTCs can be isolated inmost epithelial can-
cers, where they represent a surrogate marker of tumor cells
in transit through circulation (Alix-Panabieres and Pantel,
2013; Yu et al., 2011). The results of 300 clinical trials have
revealed the prognostic relevance of CTC counts with respect
to metastatic progression. In addition to the counts, the anal-
ysis of surface markers expressed by CTCs can be used to
monitor response to therapy and treatment-driven clonal se-
lection (Mitra et al., 2015). CTCs benefit from signals that
attenuate the apoptotic outcome in circulation such as the
mesenchymal transformation, stromal-derived factors, or
interepithelial cell junctions (Mani et al., 2008; Duda et al.,
2010; Yu et al., 2012). Recent work suggests that CTC clusters
derived from oligoclonal clusters of primary tumor cells are
rare but represent a metastasis-competent subset of CTCs
when compared with single CTCs in a process that is depen-
dent on the expression of Plakoglobin (Aceto et al., 2014).
At the cellular level, latency is often considered as
dormancy. Dormancy is not a unique feature of cancer cells.
Indeed, periods of dormancy and activation are essential for
the self-renewal capacities of some adult stem cells including
hematopoietic stem cells (HSCs) (Trumpp et al., 2010).
Dormant HSCs reside in the niches within the cavities of
trabecular bone almost ultimately in the G0 phase of the cell
cycle. Satellite cells in muscle, another example of adult
stem cells, proliferate and differentiate upon activation,
otherwise they are dormant (Tierney and Sacco, 2016). To a
certain extent, dormant properties of metastatic cells may
be attributed to the expression of tissue-specific stem cell
gene signature as was shown in studies on humanmetastatic
breast cancer cells (Lawson et al., 2015). However, the link be-
tween stem cell properties and cancer is part of an intense
debate out of the scope of this review. In the context of meta-
static dissemination and colonization, cancer cells that enter
a state of dormancy are inactive in the proliferation, whereas
the size of the dormant micrometastatic lesion is unchanged
for a period of time. Therefore, dormancy is a crucial trait
that allows DTCs and micrometastases to survive, adapt,
and colonize a distant organ in the interval of long-latentmet-
astatic progression (Nguyen et al., 2009). The eventual coloni-
zation of these organs by temporarily latent DTCs involves thePlease cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009loss of dormant metastasis-enforcing genes (Sosa et al., 2014)
or, alternatively, the gain of functions that cause growth at the
new metastatic site (Obenauf and Massague, 2015). Evidence
from genetic metastatic signatures suggests that genes whose
expression is lost in metastatic populations are the largest
group of differentially expressed genes compared to primary
tumors, thus suggesting that theymake a significant contribu-
tion to the process (Bos et al., 2009; Kang et al., 2003; Minn
et al., 2005). Various hypotheses might explain such an obser-
vation. Metastatic functions emerge not as a consequence of
factors promoting metastasis, but rather as a result of a loss
of factors supporting differentiation pathways (Casanova,
2012; Sparmann and van Lohuizen, 2006). The seeding and
establishment of micrometastases requires the loss of epithe-
lial differentiation features or gain of EMT genes (Celia-
Terrassa et al., 2012). These processes are transiently acquired
during the early steps of the metastatic cascade and they
endow DTCs with a more plastic phenotype, which may sup-
port migration, invasion, homing and initiation. It is clinically
well established that breast cancer metastases show an
epithelial differentiated phenotype. This paradox has been
explained, in part, by the mesenchymal-to-epithelial transi-
tion (MET) which may contribute to awakening cancer cells
and colonization of a distant organ (Ocana et al., 2012). Both
differentiated and cancer stem cell-like cells show slow prolif-
eration or quiescent behaviors that dormant metastatic cells
turn to their advantage under stress conditions such as
chemotherapy regimens. Alternatively, the capacity of meta-
static dormant cells to evade clearance by the immune
response may also be central to ensuring overt colonization.
Genetic or epigenetic alterations in the DTC population, sys-
temic or local changes in the microenvironment, or a combi-
nation of these factors might eventually endow surviving
DTCs with full competence for aggressive colonization.
In this context, the oncogenic background and the micro-
environment may have important roles in inducing metasta-
tic latency. Recent findings suggest that a microenvironment
supportive of or restrictive for the regulation of dormancy
phenotypes is crucial to provide stress signaling, autophagy,
stem cell, immune and vascular niches (Sosa et al., 2014).
For example, in the PyMT mouse model, tumor cells lacking
b1 integrins fail to sense fibronectin as an environmental
cue, resulting in growth arrest (White et al., 2004). Strikingly,
DTCs are found in MMTV-ERBB2 mice, but these animals do
not develop bone metastasis. However, when DTCs are trans-
planted into lethally irradiated wild-type siblings, ERBB2þ
bone marrow transplant recipients develop bone marrow car-
cinosis. This observation thus suggests that signals encoded
in specific microenvironments govern DTC fate (Sequeira
et al., 2007).5. Dormancy mechanisms in metastatic cancer
progression
Broadly defined, tumor dormancy is an arrest in tumor
growth, which may occur during the formation of primary tu-
mors or after dissemination to distant organs. However, pri-
mary tumor dormancy and metastatic dormancy appear to
be distinct processes. The latter is often explained as a resultr cell dormancy, Molecular Oncology (2016), http://dx.doi.org/
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(Giancotti, 2013). Several distinct mechanisms have been pro-
posed to maintain single cell dormancy and dormant micro-
metastasis, including cellular, angiogenic and
immunological processes. All of these contribute to the
dormant period and involve various factors, such as genetic
traits, tumor microenvironment components, and cancer
therapeutics (Osisami and Keller, 2013) (Figure 4).
5.1. Solitary cell dormancy
During metastatic dormancy, a single DTC can undergo
growth arrest, which is called cellular dormancy or solitary
cell dormancy. In contrast, the expansion of a dividing tumor
cell population in micrometastatic lesions is antagonized by a
process termed tumormass dormancy. Cellular dormancy oc-
curs when a DTC enters a state of quiescence accompanied by
decreased expression of proliferationmarker Ki67. In contrast
to mostly irreversible senescence, G0/G1 cell cycle arrest in
the quiescent phase is likely to be responsible for cellular
dormancy, hence cells are able to leave a dormant state and
proliferation is re-activated. Cell cycle arrest can be induced
in response tomitogens, stress factors or other factors present
in the host organ microenvironment (Osisami and Keller,
2013). To ensure their survival in the arrest phase, DTCs alter
signaling pathways that coordinate metabolic homeostasis.
The inhibition of the PI3K-AKT pathway is correlated with
the dormancy phenotype inDTC-derived cell lines frombreast
cancer patients (Balz et al., 2012) and dormant head and neck
squamous cell carcinoma cell lines (Schewe and Aguirre-
Ghiso, 2008).
Stress signals stemming from the foreign microenviron-
ment have also been proposed to induce dormancy in DTCs.
Although reduced mitogenic signaling can trigger quiescence,
specific kinases, such as dual specificity tyrosine
phosphorylation-regulated kinase 1B (DYRK1B), can trigger
this stage (Deng et al., 2009; Jin et al., 2009). In pancreatic
and ovarian cancer cells, DYRK1B blocks G0/G1/S transitionPI3K-AKT
p38 >
Cell arrest
ERK
G2
M
G1S
G0
G
S
CELLULAR DORMANCY
Ki67-
Figure 4 eMechanisms of cancer dormancy. Metastatic dormancy is induc
(red) mechanisms, which contribute to dormancy in different proportions. S
cycle, is mediated by different signaling pathways including PI3K-AKT low
(right) proliferation is balanced by cell death due to lack of blood supply an
for a proliferating cell, CaspD depicts an apoptotic cell.
Please cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009machinery proteins, including cyclin D1, CDK4 and p27
(Deng et al., 2009; Ewton et al., 2011). Similarly, mitogen-
activated kinases such as MKK4 (MAPKK4), can induce
dormancy in prostate and ovarian cancer cells by activation
of JNK pathway (Hickson et al., 2006; Vander Griend et al.,
2005). In a spontaneous prostate cancer metastasis model,
MKK7 suppress cancer cells formation of lung metastases by
inhibiting the ability of disseminated cells to colonize the
distant tissue. Factors secreted by the microenvironment,
such as mesenchymal cell-derived bone morphogenetic pro-
teins (BMPs) and growth arrest-specific 6 (GAS6) produced by
osteoblasts can directly inhibit DTC proliferation (Kobayashi
et al., 2011; Shiozawa et al., 2010). In prostate cancer bone
metastasis, the secretion of BMP7 activates the metastasis
suppressor gene N-myc downstream-regulated gene 1
(NDGR1), thereby inducing dormancy. This subsequently leads
to an increase in mitogen-activated protein kinase p38 (p38
MAPK) activation, cell cycle inhibitor p21 expression, and
cell cycle arrest (Kobayashi et al., 2011). Leukemia and pros-
tate cancer cells often reside in the bone marrow and they
are therefore sensitive to GAS6-driven dormancy (Shiozawa
et al., 2010). Breast cancer cells also bypass BMP-mediated
dormancy by expressing Coco, a BMP ligand antagonist that
induces lung-specific colonization (Gao et al., 2012). Recently,
latent competent human breast and lung carcinoma cells
have been proposed to express stem-cell-like SOX transcrip-
tion factors, whichdthrough the expression of WNT inhibitor
DKK1 (dickkopf WNT signaling pathway inhibitor 1)dself-
impose a slow proliferating state (Malladi et al., 2016). Cross-
talk between mitogen- and stress-induced signaling is also
important for the induction of single cell dormancy. The
extracellular signal-regulated kinase (ERK1/2) to p38 MAPK ra-
tio regulates the cell cycle since high levels of ERK1/2 activity
favor proliferation. Upon downregulation of urokinase plas-
minogen activator receptor (uPAR), squamous carcinoma cells
enter dormancy as a result of a higher ratio of p38 over ERK1/2.
Increased p38 activity triggers the activation of the unfolded
protein response (UPR), which upregulates the transcriptionCD4
CD8
NK
2
M
G1
G0
VEGF
TSP-1
HSP27
TUMOR MASS DORMANCY
Casp+Ki67+
Immune surveillance
Angiogenesis impairment
ed and maintained by cellular (yellow), angiogenic (blue) and immune
olitary cell dormancy (cellular dormancy), defined as arrest in the cell
signaling and high p38 over ERK activity. In tumor mass dormancy
d immune surveillance. Ki67L indicates an arrested cell, Ki67D states
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MOLONC844_proof ■ 12 October 2016 ■ 7/13factor ATF6, thus promoting cell arrest and survival (Aguirre-
Ghiso et al., 2001, 2003). These observations support the
notion that the activation of stress signaling pathways in-
duces a sustained state of quiescence linked to dormancy.
5.2. Tumor mass dormancy
In contrast to single cell dormancy caused by the arrested pro-
liferation of solitary DTCs, the expansion of micrometastatic
lesions can be inhibited by similar rates of proliferation and
apoptosis. To a certain extent, cell growth arrest occurs in tu-
mormass dormancy; however, tumor cells inmicrometastatic
lesions usually divide (Figure 4). The proliferation to apoptosis
balance is caused by enforced slow proliferation, restricted
blood supply or an active immune system. All processes are
tightly regulated by the tumormicroenvironment. The signals
that sustain the dormant state are largely unknown. Similarly,
it is unknown what triggers aggressive growth and how and
when it is induced. Indeed, recent evidence indicates that it
is the soil conditions and not the number of seeds that deter-
mine the frequency of osteolytic bone metastasis. Fluores-
cently labeled disseminated human breast cancer cells,
MDA-MB-231, determined by two-photon microscopy ex vivo
were detected at much higher numbers than confirmed
growing bone metastases in experimental models (Wang
et al., 2015). Alternatively, stromal signals such as TGFb and
BMPs also inhibit tumor initiation properties and trigger
slow proliferation and quiescence. Metastasis-initiating cells
need to overcome organ-specific anti-metastatic signals to
resume growth. In head and neck squamous cell carcinoma,
TGFB2 signaling has been suggested to induce the metastasis
suppressor differentially expressed in chondrocytes 2 (DEC2),
which represses CDK4 and induces p27, thus leading to slow
cycling and quiescence (Bragado et al., 2013). Interestingly,
recent work on multiple myeloma points to the coexistence
of a limited number of Ki67þ cells in the long-lived persistent
dormant population. This observation suggests that, in
certain niches, dormant cells are activated to divide. This hy-
pothesis challenges the notion that dormancy is a synchro-
nized period of quiescence (Lawson et al., 2015).
Unfortunately, to date, little is known about the mechanisms
that sustain long-term metastatic dormancy, particularly in
contexts or niches where cell proliferation coexists as part of
tissue homeostasis and regeneration. Beyond the physical
and intrinsic immune limitations discussed below, in order
to maintain a tumor mass dormant, cell-autonomous mecha-
nisms self-impose a slow cycling feature typical of highly
differentiated cells. To this end, tumor cells in this context
may execute major cellular reprogramming changes capable
of maintaining dormancy features for extended periods; how-
ever, these may be reversible, thus allowing the acquisition of
the traits required for overt metastasis.
In order to grow beyond 1e2 mm, micrometastatic lesions
induce vessel formation by secreting angiogenic factors,
including vascular endothelial growth factor (VEGF), which
attract endothelial and immune pro-angiogenic cells (Lyden
et al., 2001; Conejo-Garcia et al., 2004; Gao et al., 2008). Howev-
er, tumor mass dormancy can be maintained by the high
expression of angiogenic suppressors or the downregulation
of pro-angiogenic chemokines (Ghajar et al., 2013; StraumePlease cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009et al., 2012). A well-known angiogenic inhibitor is
thrombospondin-1 (TSP-1). The upregulation of this molecule
in cancer leads to poor vascularization and dormancy in
in vivo models of breast cancer, glioblastoma, osteosarcoma,
and liposarcoma (Lawler, 2002). Moreover, TSP-1 secretion by
the mature endothelium induces dormancy in DTCs, thereby
indicating that this factor promotes dormancy through
various mechanisms (Ghajar et al., 2013). In addition to
secreted factors, chaperons, including heat shock 27 kDa pro-
tein (HSP27), can also regulate angiogenesis directly and by
inducing pro-angiogenic factors. The downregulation of
HSP27 protein expression in angiogenic human breast cancer
cells triggers long-term in vivo dormancy, whereas its upregu-
lation induces exit from dormancy and increases vascular
density. Furthermore, HSP27 was shown to upregulate the
secretion of the angiogenic factors belonging to the VEGF fam-
ily (Straume et al., 2012).
The third mechanism of dormancy includes the role of the
immune system in the clearance of tumor cells. The capacity
of the tumor cell to initiate growth at the secondary site can be
stochastic owing to newly established interactions between
this cell and the target microenvironment or can already be
encoded in the arriving tumor cell by attenuating the signaling
cascades emanating from the environment cues or by endow-
ing the cells with the ability to bypass the natural immune
response. Cancer cells develop in a co-evolving microenviron-
ment that suppresses immune surveillance. However,
because support is not immediately available to DTCs, most
of these cells die. In addition, immune surveillance systems,
in particular cytotoxic T cells and natural killer (NK) cells
(Eyles et al., 2010), may bemajor players in anti-metastatic ac-
tion. Immunosuppressed patients develop tumors more often
than healthy individuals. In line with this, tumor formation
and progression is higher in immunodeficient mice than in
immunocompetent counterparts (Shankaran et al., 2001). An
intact immune system recognizes and removes tumor cells
by cytolysis performed by adaptive immune cells, mainly
cytotoxic T lymphocytes. During immunoediting, low immu-
nogenic tumor cells exist in a balance with immunological
clearance. The depletion of CD4þ and CD8þ T cells in mouse
models results in escape from dormancy. These results have
been supported by clinical studies showing that a lower pro-
portion of memory T cells between the CD4þ and CD8þ cell
populations in the bone marrow of breast cancer patients
correlate with larger tumors (Feuerer et al., 2001). In additional
to immunosurveillance in primary tumors, the immune sys-
tem also regulates DTC numbers and the size of micrometa-
static lesions (Muller et al., 1998). The bone marrow of
patients with breast cancer that contains dormant DTCs also
shows high levels of several subpopulations of immune sys-
tem cells, including NK cells, macrophages, and T lympho-
cytes (Feuerer et al., 2001). Therefore, the immune system
recognizes these DTCs, and memory T lymphocytes migrate
to the bone marrow to control metastatic spread. Indeed,
depletion of these immune cell populations increases overt
metastasis (Malladi et al., 2016; Bidwell et al., 2012; Smyth
et al., 1999), and inhibition of a negative regulator and specific
NK tyrosine kinase, Mer, suppressesmetastasis (Paolino et al.,
2014). NK cell activity is suppressed in patients with advanced
metastatic disease. NK cell activation is tightly regulated byr cell dormancy, Molecular Oncology (2016), http://dx.doi.org/
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MOLONC844_proof ■ 12 October 2016 ■ 8/13activating and inhibitory signals that propagate from a panel
of NK cell receptors (NKRs) expressed at the cell surface. These
include three families of receptor inhibitors (C94/NKG2A, KIR
and LILRB1/ILT2) that recognize class I human leukocyte anti-
gen (HLA) molecules normally expressed in all cells. The acti-
vating NKRs include CD16 and activating KIR, NKG2D and
NCR(NKp30, NKp46, NKp44) (Moretta et al., 2006). CD16-
expressing NK cells have been proposed to mediate
antibody-dependent cellular cytotoxicity (ADCC) upon
antibody-mediated targeted therapies, whereas the inhibitory
KIR-expressing NK cell population is the most functionally
competent (high levels of Granzyme B). The action of NK
and T cells is regulated by tumor cells on the basis of class I
HLA expression. Variations in the expression of these pro-
teins, together with programmed death-ligand 1 (PD-1) li-
gands in DTCs, may define the fate of these cells in response
to the cytotoxic action of NK and T cells. Identifying the bal-
ance of signals that affects DTC turnover and the properties
required for these cells to maintain a viable state and escape
the immune system would provide valuable clues for thera-
peutic intervention against minimal residual disease.
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1016. Exit from dormancy
A set of potential dormant metastasis exit mechanisms has
recently been described; however, these mechanisms are
strongly determined by the tissue to be colonized. Given that
in long latent tumor types such as prostate and ERþ breast
cancer dissemination occurs mainly in the bone, we focused
on the specific mechanisms governing this process in this
site (Coleman, 2001). The process of bone colonization starts
by pre-metastatic niche formation, before the arrival ofEndothelial cell
PERIVASCULAR NICHE H
Mes
TGFβ Wnt Periostin
βCat SRC
Signaling
B
LO
O
D
 V
E
S
S
E
L 
(S
IN
U
S
O
ID
)
BON
META
Figure 5 e The metastatic niches in the bone marrow. In order to survive,
niche. Niche occupancy depends of the pro-survival interactions between me
of bone marrow (red or blue). In perivascular niche, sprouting neovasculat
endothelial cells (red) and Wnt signaling activation in metastatic cells. Mes
by CXCR4 receptor binding in metastatic cells, signals through PI3K-AKT
activation. DTC can also interact with osteogenic cells (blue) by formation o
metastatic cells E-cadherin. Therefore, mTOR signaling is activated prom
Please cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009metastatic CTCs. The primary tumor conditions the bone
marrow by secreting soluble factors that target cells in the
bone microenvironment (Weilbaecher et al., 2011). Molecules
such heparanase, osteopontin, and lysyl oxidase facilitate
the invasion, survival, and proliferation of metastatic breast
cancer cells (Kelly et al., 2005; Ibrahim et al., 2000; Cox et al.,
2015). After extravasation, metastatic DTCs may occupy
various native niches in the bone, including hematopoietic
stem cell, osteogenic and perivascular, to benefit from physi-
ological signals promoting cell survival in the new environ-
ment (Figure 5). The perivascular niche is localized around
blood capillaries and, depending on the activity of endothe-
lium, it secrets tumor-suppressive or -promoting signals.
DTCs localized near mature vessels are usually maintained
in a quiescent state by endothelium-derived TSP-1, which is
a potent tumor suppressor (Ghajar et al., 2013). As a result of
neovascular sprouting, which disrupts vessel homeostasis,
endothelial cells release more tumor-promoting signals,
such as ECM molecules, and growth factors, including perios-
tin and active TGFb, which drive micrometastatic outgrowth
(Ghajar et al., 2013) (Figure 5). Since the bone marrow is
permissive for the homing and residence of HSCs, the HSC
niche seems to be a protective environment for DTCs because
it provides pro-survival chemokines that sustain the viability
of metastatic cells (Yoneda, 2000). For example, the secretion
of stromal cell-derived factor 1 (SDF1; also known as
CXCL12) by mesenchymal cells in the bone marrow promotes
the survival of metastatic cells that express C-X-C chemokine
receptor 4 (CXCR4) (Kang et al., 2003). Moreover, overexpres-
sion of the tyrosine kinase SRC in DTCs amplifies the
CXCR4-induced activation of the PI3K-AKT pathway (Zhang
et al., 2009) (Figure 5). The third niche that DTCs occupy is
the osteogenic niche, where interactions with the stromaSC NICHE OSTEOGENIC NICHE
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MOLONC844_proof ■ 12 October 2016 ■ 9/13enhance mTOR activity and drive progression from single
cells to micrometastases prior to osteolysis (Wang et al.,
2015) (Figure 5). These distinct mechanisms that metastatic
cells use to survive in the bone microenvironment and to
exit dormancy reflect the heterogeneity of metastatic popula-
tions. Niche occupancy depends on the traits that cells ac-
quire during the metastatic cascade, followed by the
interactions between tumor and host cells. Therefore, DTCs
home to the bone, start to proliferate (often after a period of
dormancy), form micrometastatic lesions, and finally induce
vicious cycles of bone lysis and tumor growth.
In the final phase of metastatic colonization, cancer cells
control the bone microenvironment to activate osteoclasts
and suppress bone formation. This is achieved by paracrine
crosstalk among cancer cells, osteoblasts, osteoclasts, and the
bone matrix (Figure 6). Cancer cells secrete osteolytic factors
that activate bone-resorbing osteoclasts. To activate osteo-
blasts, metastatic cells produce cytokines and growth factors,
including parathyroid hormone-like protein (PTHrP), inter-
leukin (IL)-11, IL-6, IL-8, VEGF, and tumor necrosis factor (TNF-
a) (extensively reviewed in (Weilbaecher et al., 2011; Kozlow
and Guise, 2005)). As a result, osteoblasts release soluble recep-
tor activator of nuclear factor kappa-B ligand (RANKL) and inac-
tivate its antagonist osteoprotegerin (OPG). The ratio of RANKL
to OPG is critical for osteoclast activation since OPG prevents
RANKL from binding to its receptor RANK. Once activated
upon ligand binding, the multinucleated osteoclasts attach to
the bone surface and release acid and proteolytic enzymes,
such as cathepsin K and matrix metalloproteinases (MMP) to
resorb the bone matrix. Osteolysis releases growth factors
stored in thematrix, includingTGFb, insulin-likegrowth factors
(IGFs), and BMPs, as well as calcium ions, into the bone micro-
environment. In addition to tumor growth enhancement, in
metastatic cells, TGFb activates both Smad-dependent andFigure 6 e The bone metastasis vicious cycle. During the osteolytic cycle, m
stimulate osteoclastic bone resorption directly by MMP and VCAM1 (grey
(orange). Activated osteoblasts secret osteoclastic factors (blue) mainly RA
(yellow). The consequence of increased resorption is the release of growth fa
further stimulating their growth. Ca2D that stands for calcium ions.
Please cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009Smad-independent signal pathways to induce PTHrP (Kang
et al., 2005; Yin et al., 1999). Therefore, tumor growth is stimu-
lated, leading to the production of additional osteolytic and
osteoblastic factors and resulting in the vicious cycle of bone
metastasis. In addition, bone resorption can be promoted by
the Notch signaling pathway, which results in IL-6 secretion
upon binding of tumor-derived JAGGED-1 (JAG-1) to osteoblasts
(Sethi et al., 2011).7. Clinical and experimental implications
The new extended treatments and increase in overall survival
achieved with current therapies have highlighted the need for
new diagnostic tests to identify patients at high risk of
suffering late metastasis and, hence, those that could benefit
most from a rational system that would apply treatments to
prevent survival of disseminated tumor cells in the bone
marrow. Presumably, systemic therapy delivered after tumor
removal aims to prevent relapse. However, the current phar-
macological arsenal used in the adjuvant setting (chemo-
therapy) targets growing tumor cells rather than
dissemination. The systemic nature of the metastatic disease,
the heterogeneity of metastatic tumors, the multitude of
interconnected pathways, and the resistance mechanisms
suggest a difficult pharmacological approach. Collectively,
these facts imply that attention should be directed to prevent-
ingmetastasis rather than treating it(Coleman, 2012a,b) Q. Thus,
focus on high-risk patients is pivotal to effectively eliminate
residual disseminated disease (Pavlovic et al., 2015). Unfortu-
nately, when tested in the overall cancer population in the
preventive adjuvant setting, inconclusive results have been
reported for bone-modifying drugs to date, in spite of their
use in clinical practice to control bone metastasis morbidityetastatic cells in the bone microenvironment produce molecules that
), or indirectly through osteoblast activation by osteoblastic factors
NKL to promote bone degradation by proteases and collagenases
ctors from the bone matrix (grey) that feed back to the metastatic cells,
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MOLONC844_proof ■ 12 October 2016 ■ 10/13(skeletal related events and hypercalcemia) (Smith et al., 2015;
Coleman, 2012a,b). A better understanding of the bases of
metastatic dormancy and colonization and better drugs are
needed to develop improved treatments to address this unmet
medical need. To this end, drugs that could prevent metas-
tasis by targeting metastatic cell-autonomous functions that
sustain dormancy ormechanisms that support their existence
in the preventive setting represent a new opportunity to elim-
inate minimal residual disease, thus enhancing the quality of
patients’ lives.
To date, there are few experimental models available to
study the latency phase of tumor growth. Particularly, the
striking differences in the growth kinetics between cancer
cell lines and mouse models compared to human cancer
makes this studies difficult (Klein, 2009). Thus, suitable exper-
imentalmodelswould require a latent phase that lasts up to at
least 6e8 weeks. Recent studies have provided a number of
models. Using a human ER breast cancer cell line (Lu et al.,
2011), a single clone population was isolated that infrequently
formed overt metastases from dormant micrometastases in
the bone. Also, mathematical modeling showed that patients
with long-latent breast cancer have between 1 and 5microme-
tastases at 10 years post-resection, thereby indicating that
small numbers of lesions maintain dormancy (Willis et al.,
2010). Several lines of evidence indicate that the quiescence
of single cells is an important contributor to long latency.
DTCs in the bone marrow of breast cancer patients are largely
non-proliferative and, in contrast to CTCs, can persist in the
target organs for long periods (Klein, 2011). A recent report
showed that, upon orthotropic injection, human ER breast
cancer cells disseminate to various organs, including liver,
lung, brain, and bonemarrow, and undergo cellular dormancy
before the formation of micrometastases (Ghajar et al., 2013).
Also, in a syngeneic mouse model of breast cancer, dormancy
is governed by the quiescence of solitary cells. Single 4TO7
cells enter arrest immediately upon infiltrating the lung and
are therefore unable to form micrometastatic lesions (Gao
et al., 2012). Currently, cellular dormancy is associated mainly
with solitary cells, while dormantmacrometastatic lesions are
considered to consist of actively proliferating cells balanced
with the same number of apoptotic cells (Wells et al., 2013).
Moreover, these two forms of dormancy were thought to be
exclusive and sequential events. However, recent studies sug-
gest that G0 cell dormancy is responsible not only for the ar-
rest of solitary cells, but also contributes to tumor mass
dormancy, thereby suggesting that a variety of mechanisms
can synergistically promote long latency (Lawson et al.,
2015). Thus, mechanisms of cellular dormancy manifested
as quiescence are not exclusive to solitary cells but contribute
to tumor mass dormancy. It is unclear how slow cycling and
quiescence are imposed in a cell-autonomous manner, how
the niche specifically contributes to such a process, and how
a continuously dormant single cell or tumor mass evolves
and acquires properties that support symptomaticmetastasis.
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1308. Concluding remarks
An important goal of current research is to provide new drugs
to increase the overall survival of cancer patients. AlthoughPlease cite this article in press as: Gomis, R.R., Gawrzak, S., Tumo
10.1016/j.molonc.2016.09.009new systemic therapies and surgical improvements have
had a significant impact on the field in recent years, many pa-
tients still develop metastasis. To overcome current limita-
tions, metastasis prevention seems a far more logical option
than the treatment of advanced metastatic disease. For
example, mTOR inhibitors have an impact on overall survival
of advanced ERþ breast metastatic cancer, but this effect is
limited in time. Thus, themost plausible and challenging win-
dow opportunity for new treatments to prevent metastasis is
by modifying the adjuvant setting defined by dormancy. This
period reflects the capacity of disseminated tumor cells or
micrometastases to persist at low numbers for long periods
after tumor resection remaining as asymptomatic residual
disease. However, to effectively target this process, deeper
knowledge of the cancer patients at risk of distant metastasis
is needed to effectively deliver proper drugs. In addition, a
greater understating of the mechanisms underlying tumor
dormancy and how these are overcome to allow metastasis
regrow are paramount if we are to find new strategies to tackle
asymptomatic residual disease.Conflict of interest
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